Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 35

1.

Consent to discuss participation in research: a pilot study.

Walker S, Potts J, Martos L, Barrera A, Hancock M, Bell S, Geddes J, Cipriani A, Henshall C.

Evid Based Ment Health. 2019 Sep 26. pii: ebmental-2019-300116. doi: 10.1136/ebmental-2019-300116. [Epub ahead of print]

PMID:
31558561
2.

Identification of 58 Mutations (26 Novel) in 94 of 109 Symptomatic Spanish Probands with Protein C Deficiency.

Martos L, Fernández-Pardo Á, López-Fernández MF, Ibáñez F, Herrero S, Tàssies D, González-Porras JR, Solmoirago MJ, Costa MJ, Reverter JC, Marco P, Roldán V, Lecumberri R, Velasco F, Oto J, Iruin G, Alonso MN, Vayá A, Bonanad S, Ferrando F, Martí E, Cid AR, Plana E, Oña F, Cuesta I, González-López TJ, España F, Medina P, Navarro S; Working Group of the Spanish Society of Thrombosis Haemostasis (SETH).

Thromb Haemost. 2019 Sep;119(9):1409-1418. doi: 10.1055/s-0039-1692440. Epub 2019 Jun 29.

PMID:
31254973
3.

α2-Macroglobulin Is a Significant In Vivo Inhibitor of Activated Protein C and Low APC:α2M Levels Are Associated with Venous Thromboembolism.

Martos L, Ramón LA, Oto J, Fernández-Pardo Á, Bonanad S, Cid AR, Gruber A, Griffin JH, España F, Navarro S, Medina P.

Thromb Haemost. 2018 Apr;118(4):630-638. doi: 10.1055/s-0038-1629902. Epub 2018 Feb 15.

4.

Comparison of protocols and RNA carriers for plasma miRNA isolation. Unraveling RNA carrier influence on miRNA isolation.

Ramón-Núñez LA, Martos L, Fernández-Pardo Á, Oto J, Medina P, España F, Navarro S.

PLoS One. 2017 Oct 27;12(10):e0187005. doi: 10.1371/journal.pone.0187005. eCollection 2017.

5.

Lack of association between alopecia areata and HLA class I and II in a southeastern Brazilian population.

Barbosa ÂM, Prestes-Carneiro LE, Sobral AR, Sakiyama MJ, Lemos BC, Abreu MA, Martos LL, Moliterno RA.

An Bras Dermatol. 2016 May-Jun;91(3):284-9. doi: 10.1590/abd1806-4841.20164250.

6.

A simplified assay for the quantification of circulating activated protein C.

Martos L, Bonanad S, Ramón LA, Cid AR, Bonet E, Corral J, Miralles M, España F, Navarro S, Medina P.

Clin Chim Acta. 2016 Aug 1;459:101-104. doi: 10.1016/j.cca.2016.05.025. Epub 2016 Jun 2.

PMID:
27262823
7.

New patient assessment in old age psychiatry: the importance of risk assessment.

Hemsley S, McKnight R, Anwar A, Jones S, Martos L.

BJPsych Bull. 2015 Oct;39(5):227-32. doi: 10.1192/pb.bp.113.046342.

8.

A collaborative strategy to improve geriatric medical education.

Cockbain BC, Thompson S, Salisbury H, Mitter P, Martos L.

Age Ageing. 2015 Nov;44(6):1036-9. doi: 10.1093/ageing/afv100. Epub 2015 Aug 10.

PMID:
26265672
9.

Breath methane in functional constipation: response to treatment with Ispaghula husk.

Vega AB, Perelló A, Martos L, García Bayo I, García M, Andreu V, Abad A, Barenys M.

Neurogastroenterol Motil. 2015 Jul;27(7):945-53. doi: 10.1111/nmo.12568. Epub 2015 May 7.

PMID:
25952409
10.

Is brain natriuretic peptide a reliable biomarker of hydration status in all peritoneal dialysis patients?

Crepaldi C, Rosner M, Teixeira C, Martos LB, Martino FK, Rodighiero MP, Ronco C.

Blood Purif. 2014;37(3):238-42. doi: 10.1159/000362155. Epub 2014 Jun 12.

11.

Functional analysis of two haplotypes of the human endothelial protein C receptor gene.

Medina P, Navarro S, Bonet E, Martos L, Estellés A, Bertina RM, Vos HL, España F.

Arterioscler Thromb Vasc Biol. 2014 Mar;34(3):684-90. doi: 10.1161/ATVBAHA.113.302518. Epub 2014 Jan 16.

PMID:
24436369
12.

Association of the thrombomodulin gene c.1418C>T polymorphism with thrombomodulin levels and with venous thrombosis risk.

Navarro S, Medina P, Bonet E, Corral J, Martínez-Sales V, Martos L, Rivera M, Roselló-Lletí E, Alberca I, Roldán V, Mira Y, Ferrando F, Estellés A, Vicente V, Bertina RM, España F.

Arterioscler Thromb Vasc Biol. 2013 Jun;33(6):1435-40. doi: 10.1161/ATVBAHA.113.301360. Epub 2013 Mar 21.

PMID:
23520161
13.

Effects of oral anticoagulant therapy and haplotype 1 of the endothelial protein C receptor gene on activated protein C levels.

Medina P, Bonet E, Navarro S, Martos L, Estellés A, Ferrando F, Vicente V, Bertina RM, España F.

Thromb Haemost. 2012 Mar;107(3):448-57. doi: 10.1160/TH11-07-0510. Epub 2012 Jan 25.

PMID:
22273845
14.

The endothelial cell protein C receptor: its role in thrombosis.

Navarro S, Bonet E, Estellés A, Montes R, Hermida J, Martos L, España F, Medina P.

Thromb Res. 2011 Nov;128(5):410-6. doi: 10.1016/j.thromres.2011.08.001. Epub 2011 Sep 7. Review.

PMID:
21903242
15.

Haplotypes of the endothelial protein C receptor gene and Behçet's disease.

Navarro S, Bonet E, Medina P, Martos L, Ricart JM, Vayá A, Todolí J, Fontcuberta J, Estellés A, España F.

Thromb Res. 2012 Apr;129(4):459-64. doi: 10.1016/j.thromres.2011.07.032. Epub 2011 Aug 17.

PMID:
21851971
16.

TLR signaling pathway in patients with sepsis.

Salomão R, Martins PS, Brunialti MK, Fernandes Mda L, Martos LS, Mendes ME, Gomes NE, Rigato O.

Shock. 2008 Oct;30 Suppl 1:73-7. doi: 10.1097/SHK.0b013e318181af2a. Review.

PMID:
18704004
17.

Expression of cell surface receptors and oxidative metabolism modulation in the clinical continuum of sepsis.

Martins PS, Brunialti MK, Martos LS, Machado FR, Assunçao MS, Blecher S, Salomao R.

Crit Care. 2008;12(1):R25. doi: 10.1186/cc6801. Epub 2008 Feb 13.

18.

Bacterial recognition and induced cell activation in sepsis.

Martins PS, Brunialti MK, da Luz Fernandes M, Martos LS, Gomes NE, Rigato O, Salomao R.

Endocr Metab Immune Disord Drug Targets. 2006 Jun;6(2):183-91. Review.

PMID:
16787293
19.

[The concept of myocardial infarct rehabilitation in phase III].

Quittan M, Resch KL, Lukacs P, Martos L, Vavrovsky G, Raith M, Frank D, Mayer H, Plenk I, Rathkolb O, et al.

Wien Med Wochenschr. 1994;144(4):74-7. German.

PMID:
8023525
20.

Formation of syncytia in human lymphoblastoid cells infected with type C viruses.

Hampar B, Rand KH, Lerner RA, Del Villano BC Jr, McAllister RM, Martos LM, Derge JG, Long CW, Gilden RV.

Virology. 1973 Oct;55(2):453-63. No abstract available.

PMID:
4355114
21.

Identification of a critical period during the S phase for activation of the Epstein-Barr virus by 5-iododeoxyuridine.

Derge JG, Martos LM, Tagamets MA, Chang SY, Chakrabarty M.

Nat New Biol. 1973 Aug 15;244(137):214-7. No abstract available.

PMID:
4353682
22.

Sequence of spontaneous Epstein-Barr virus activation and selective DNA synthesis in activated cells in the presence of hydroxyurea.

Hampar B, Derge JG, Martos LM, Tagamets MA, Burroughs MA.

Proc Natl Acad Sci U S A. 1972 Sep;69(9):2589-93.

24.

Persistence of a repressed Epstein-Barr virus genome in Burkitt lymphoma cells made resistant to 5-bromodeoxyuridine.

Hampar B, Derge JG, Martos LM, Walker JL.

Proc Natl Acad Sci U S A. 1971 Dec;68(12):3185-9.

25.
26.

Serologic evidence that a herpes-type virus is the etiologic agent of heterophile-positive infectious mononucleosis.

Hampar B, Hsu KC, Martos LM, Walker JL.

Proc Natl Acad Sci U S A. 1971 Jul;68(7):1407-11.

27.

Serologic classification of Herpes simplex viruses.

Hampar B, Miyamoto K, Martos LM.

J Immunol. 1971 Feb;106(2):580-2. No abstract available.

PMID:
5313217
28.

Replication of murine and feline RNA-containing C-type viruses in human lymphoblastoid cells.

Hampar B, Kelloff GJ, Martos LM, Oroszlan S, Gilden RV, Walker JL.

Nature. 1970 Nov 28;228(5274):857-8. No abstract available.

PMID:
4320053
29.

Immunoferritin and immunofluorescent studies with Epstein-Barr virus and herpes simplex virus by use of human sera and hyperimmune rabbit sera.

Hampar B, Gerber P, Hsu KC, Martos LM, Walker JL, Sigüenza RF, Wells GA.

J Natl Cancer Inst. 1970 Jul;45(1):75-85. No abstract available.

PMID:
4194657
30.

Late 19S rabbit antibody neutralization test for differentiating herpes simplex virus types 1 and 2.

Hampar B, Martos LM, Chakrabarty M, Burroughs MA.

J Immunol. 1970 Mar;104(3):593-8. No abstract available.

PMID:
4314178
31.

Preparation of immune rabbit sera with neutralizing activity against human cytomegalovirus and varicella-zoster virus.

Martos LM, Ablashi DV, Gilden RV, Sigüenza RF, Hampar B.

J Gen Virol. 1970;7(2):169-71. No abstract available.

PMID:
4316778
32.

Differentiation of cross-reacting simian cytomegalovirus strains by late 19S rabbit neutralizing antibodies.

Hampar B, Martos LM, Ablashi DV, Siguënza RF, Wells GA.

J Immunol. 1969 Nov;103(5):1155-6. No abstract available.

PMID:
4310839
33.

Correlation between the neutralizing activity of human serum against Herpes simplex virus and a simian herpesvirus (SA8).

Hampar B, Stevens DA, Martos LM, Ablashi DV, Burroughs MA, Wells GA.

J Immunol. 1969 Feb;102(2):397-403. No abstract available.

PMID:
4303793
34.

Preparation of rabbit immune serum with neutralizing activity against a simian cytomegalovirus (SA6).

Ablashi DV, Martos LM, Gilden RV, Hampar B.

J Immunol. 1969 Jan;102(1):263-5. No abstract available.

PMID:
4303878
35.

Supplemental Content

Loading ...
Support Center